Research Presented at 2020 AACR Virtual Annual Meeting
The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model
Triple I/O Combination to Be Administered to Patients Who Failed I/O in Second Half of 2020
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology (I/O) therapies, today announced new preclinical research findings that indicate BeyondSprings lead asset, Plinabulin, enhances immuno-radiotherapy for cancer patients. The results of this preclinical study was highlighted in a poster presentation titled, Plinabulin, a microtubule destabilizing agent, improves tumor control by enhancing dendritic cell maturation and CD8 T cell infiltration in combination with immunoradiotherapy, at this years American Association for Cancer Research (AACR) Virtual Annual Meeting on June 22, 2020.
Based on these preclinical findings, including a 100% complete response of the triple I/O combination of Plinabulin, anti-PD-1, and radiation in a PD-1 antibody non-responsive model, the compound is being advanced toward a Phase 1 clinical trial in patients who failed or progressed on PD-1 / PD-L1 antibody treatments. Principal investigator Steven H. Lin,M.D., Ph.D., associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, presented the research data.
The experiments from my lab demonstrated that Plinabulin treatment in murine cancer models leads to activation of antigen-presenting dendritic cells, said Dr. Lin. The combination therapy with Plinabulin, anti-PD-1 therapy and radiation therapy further activated the immune system, resulting in increased T-cell activation, which is associated with increased tumor regressions.
Additional data highlights include:
The above data presentation is available on the Posters page of the BeyondSprings website at: https://www.beyondspringpharma.com/conferences/list.aspx?lcid=3.
Peer-reviewed 2019 publications in Chem and Cell Reports demonstrated that Plinabulin is differentiated from all other tubulin-targeted agents through its binding site and kinetics and is among the most potent agents that induce dendritic cell maturation. Dendritic cells are key immune cell types in the activation of the immune system against cancer cells, but currently approved immuno-oncology agents, such as antibodies to PD-1, only take the brakes off of T-cells without activating antigen-presenting cells that stimulate T-cells to attack foreign proteins expressed by cancer cells.
We believe that the activation of dendritic cells is a key to unlocking the next boost to the efficacy of immuno-oncology agents, said Dr. James Tonra, BeyondSprings Chief Scientific Officer. Activated dendritic cells present foreign tumor antigens to T-cells to induce cancer-directed immune attacks. Thus, adding this critical step of dendritic cell activation in the immune cascade to the established effects of immune checkpoint inhibition therapies is expected to increase overall anti-cancer efficacy in the clinic. Our anti-cancer strategy was to activate dendritic cells and T-cells, in combination with checkpoint inhibition and to add onto the benefits of neoantigen generation and immune activation from radiotherapy, as Plinabulin serves as the key to reverse the tumor non-response to PD-1/PD-L1 antibodies. The data strongly indicates that this triple combination has enough potential to move into clinical testing to help patients who failed or had progressed on anti-PD-1/PD-L1 targeted therapy, a severely unmet medical need.
About BeyondSpringBeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSprings lead asset, first-in-class agent Plinabulin as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.
About PlinabulinPlinabulin, BeyondSprings lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.
Cautionary Note Regarding Forward-Looking StatementsThis press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSprings most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Media ContactsCaitlin Kasunich / Raquel ConaKCSA Strategic Communications212.896.1241 / 212.896.1276ckasunich@kcsa.com / rcona@kcsa.com
The rest is here:
New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin - BioSpace
- Cardiovascular Glossary A-Z (All) | Texas Heart Institute - January 4th, 2023
- ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) - Business Wire - September 25th, 2022
- GVHD in the Context of Stem Cell or Allogeneic Transplant - Cancer Network - August 22nd, 2022
- De-extinction Company Aims to Resurrect the Tasmanian Tiger - Scientific American - August 22nd, 2022
- Dean Kamen on the power of celebrating your own obsoletion - TechCrunch - July 27th, 2022
- Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL - OncLive - July 27th, 2022
- Unanticipated findings cast new light on the genetic regulation of different brain tumors - Baylor College of Medicine - July 27th, 2022
- Chaotic response in Uvalde, Parkland shooter faces death penalty, mall shooting leaves 3 dead and jury selection begins in Bannon trial | Hot off the... - July 19th, 2022
- Stem Cells, Abortion, Baby Parts, & the Ukraine - Physicians for Life - June 22nd, 2022
- INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT - BioSpace - June 22nd, 2022
- Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive... - June 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 15th, 2022
- La Conner native raising funds to cure blood cancer - La Conner Weekly News - May 2nd, 2022
- CORRECTING and REPLACING -- Affimed NV - GlobeNewswire - May 2nd, 2022
- StudyFinds Blotter: Other Notable Health Research From April 28, 2022 - Study Finds - May 2nd, 2022
- Sung to lead cancer institute; Bankston wins fellowship - ASBMB Today - April 19th, 2022
- Houston teen first in Texas to become own donor to reverse sickle cell anemia - FOX 26 Houston - March 25th, 2022
- Oleic Acid, a Key to Activating the Brains Fountain of Youth - Neuroscience News - March 25th, 2022
- Stem Cell Therapy Boosts Outcomes for Some Heart Failure Patients - HealthDay - November 22nd, 2021
- Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed... - November 22nd, 2021
- BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture - Yahoo... - November 22nd, 2021
- Immatics to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancers 36th Annual Meeting - Yahoo... - November 8th, 2021
- Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual ... - Tyler Morning Telegraph - November 8th, 2021
- ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting - StreetInsider.com - November 8th, 2021
- The Power of the Immune System: New Treatment for Painful Blood Cancer Side Effect - Curetoday.com - October 28th, 2021
- Durham firm offering up to $10,000 for researchers to use its intestinal technology - WRAL Tech Wire - October 16th, 2021
- Elevated cryptic transcription emerges as a common theme in aging mammalian cells - Baylor College of Medicine News - August 31st, 2021
- Insulin-producing implants are being developed to control Type 1 diabetes - Health Europa - August 5th, 2021
- Cryptic Transcription in Mammalian Stem Cells Linked to Aging - Technology Networks - August 5th, 2021
- Overview of DLBCL - Targeted Oncology - August 5th, 2021
- The True Crime Junkies and the Curious Case of a Missing Husband - VICE - August 5th, 2021
- FROM THE LABS: Hispanic Heritage Spotlight: Interview with Dr. Nino Rainusso - Baylor College of Medicine News - November 13th, 2020
- UPMC nurse practitioner hailed 'healthcare hero' on live TV - Altoona Mirror - October 31st, 2020
- BrainStrom Cell Therapeutics (NASDAQ:BCLI) Enters Agreement With Catalent (NYSE:CTLT) For Manufacture Of Its NurOwn Cell Therapy - BP Journal - October 31st, 2020
- Dr. Daisy Ayim, Cosmetic Surgeon, ObGyn, Business Owner and Entrepreneur, Is Revolutionizing The Integration Of Women's Health And Cosmetic Care -... - October 31st, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 21st, 2020
- Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma - Science... - October 21st, 2020
- Biotechnology could change the cattle industry. Will it succeed? - Salon - September 8th, 2020
- STEM CELLS | VitaDrip IV Therapy | Texas - June 26th, 2020
- Tau: Why Alzheimer's Worsens Fast in Some, Slowly in Others - Alzforum - June 23rd, 2020
- Scholarly Perspectives on COVID-19, Part 1: This Was Only a Matter of Time - Southern Newsroom - June 23rd, 2020
- Texas Stem Cell Law Opens Door for Controversial Treatments - June 11th, 2020
- Who's to blame? These three scientists are at the heart of the Surgisphere COVID-19 scandal - Science Magazine - June 9th, 2020
- FTC ramps up enforcement with new wave of warning letters - NutraIngredients-usa.com - June 9th, 2020
- UT Student Awarded Prestigious Astronaut Scholarship - UT News | The University of Texas at Austin - June 9th, 2020
- South Sound Community Bands Together To Save Local Lives - southsoundtalk.com - May 7th, 2020
- Pfizer, NYU working on innovative coronavirus vaccine that could be ready by end of summer - NBC News - May 7th, 2020
- How industry hopes to take on COVID-19 - Bioprocess Insider - BioProcess Insider - March 8th, 2020
- Meng Hsieh, Andrew Shubin - The New York Times - March 8th, 2020
- Jimbo Fisher's Kidz1stFund, Aggie Corps of Cadets team up for Be the Match bone marrow donor registry drive - Bryan-College Station Eagle - March 2nd, 2020
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University - March 2nd, 2020
- What to do in Madison: March 2-8, 2020 - The Bozho - March 2nd, 2020
- Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com - February 27th, 2020
- Recombinetics Announces Collaboration with University of Texas Southwestern to Advance Regenerative Medicine Through Therapeutic Cell, Tissue, and... - February 27th, 2020
- Stem Cell Therapy for Joints & Spine in Austin Texas - January 28th, 2020
- El Paso scientists to deliver 3D bioprinted miniature hearts to the ISS - 3D Printing Industry - January 28th, 2020
- El Paso scientists team up for heart research project at the International Space Station - KVIA El Paso - January 28th, 2020
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra - December 18th, 2019
- Incoming Faculty Bring New Areas of Research to Rensselaer - Rensselaer Polytechnic Institute - September 24th, 2019
- Nivolumab as an addition to frontline therapy of AML in younger patients - AML Global Portal - September 24th, 2019
- Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com - September 24th, 2019
- Stem cells regrow leg's long bones - WNDU-TV - September 22nd, 2019
- A breakthrough in the battle against citrus greening - Gainesville Sun - September 22nd, 2019
- Comparing Mymetics (OTCMKTS:MYMX) & Crispr Therapeutics (OTCMKTS:CRSP) - TechNewsObserver - September 22nd, 2019
- STEM CELL THERAPY & TREATMENTS Texas Regional Health - September 10th, 2019
- Fast Facts: Stem Cells 101 Vital Record - September 10th, 2019
- Keller, TX Stem Cells | Neuropathy & Pain Centers of Texas - May 31st, 2019
- Arlington Stem Cells | Neuropathy & Pain Centers of Texas - May 1st, 2019
- Houston, Texas Stem Cell Transplants, Richmond, Sugar Land ... - April 21st, 2019
- Fort Worth Stem Cells | Neuropathy and Pain Centers of Texas - April 15th, 2019
- Stem Cell Rejuvenation Therapy | Totalhormonegenetherapy.com - April 15th, 2019
- Our Doctors - Knee Stem Cells - March 17th, 2019
- Stem Cell Treatment Center in Dallas, Texas | Stem Cell ... - March 17th, 2019
- Neuropathy & Pain Centers of Texas - Stem Cells & Neuropathy - February 6th, 2019
- Stem Cell Doctor Dallas Dr. Darcy Brunk | Dallas, Plano ... - January 25th, 2019
- Four Types of Stem Cells - Texas Right to Life - December 15th, 2018
- Texas | The Stem Cellar - December 5th, 2018
- Dallas, Texas, Stem Cells Treatment, Legal, Ft. Worth ... - November 16th, 2018
- HB810 | Right to Try Law | Texas Stem Cell Law | StemGenex - October 13th, 2018
- Shooting Up Stem Cells With Ben Greenfield The Down The ... - September 16th, 2018